How Mitochondrial-Derived Peptides, Cardiolipin Targeting and Metabolic Signaling Are Opening a New Research Frontier
Mitochondrial peptide research is rapidly changing how scientists think about one of the cell’s most familiar structures.
For decades, mitochondria were introduced primarily as the cell’s energy-producing organelles.
That description is correct—but increasingly incomplete.
Modern research has revealed mitochondria as dynamic signaling centers involved in energy metabolism, cellular stress responses, redox biology, metabolic adaptation and communication between mitochondrial and nuclear genomes.
Peptide science is now moving directly into this territory.
One direction in mitochondrial peptide research emerged from an unexpected discovery: mitochondrial DNA itself can encode small biologically active peptides, including MOTS-c.
Another took an entirely different route: engineering a peptide capable of interacting with cardiolipin, a specialized phospholipid concentrated within the inner mitochondrial membrane.
In September 2025, those worlds reached an important milestone when the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome—the first approved treatment for the disease and a drug officially described by the FDA as a mitochondrial cardiolipin binder.
This does not mean every compound associated with mitochondrial biology has suddenly become clinically validated.
It means something more scientifically significant:
Mitochondria have become a direct molecular target for peptide research.
1. Why Mitochondrial Peptide Research Extends Far Beyond ATP
Mitochondria generate much of the cellular ATP required to support biological activity, but mitochondrial biology extends considerably beyond energy production.
These organelles participate in metabolic sensing, oxidative signaling, cellular stress responses and communication with the nucleus.
Their architecture is equally important.
The inner mitochondrial membrane folds into structures called cristae, where much of the machinery responsible for oxidative phosphorylation is organized.
Embedded within that membrane is cardiolipin, an unusual phospholipid closely associated with mitochondrial membrane structure and the organization of proteins involved in bioenergetics.
This creates several possible levels at which researchers can investigate mitochondrial biology:
mitochondrial genetic signaling
mitochondrial-derived peptides
nuclear regulation of mitochondrial metabolism
inner mitochondrial membrane structure
cardiolipin interactions
cellular energy and stress-response pathways
The expansion of mitochondrial peptide research reflects the fact that peptide science is now touching several of these systems simultaneously.
2. MOTS-c: A Peptide Hidden Inside the Mitochondrial Genome
One of the most interesting discoveries in mitochondrial peptide research came from looking more closely at mitochondrial DNA.
MOTS-c — mitochondrial ORF of the twelve S rRNA type-c — is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region.
That finding challenged the traditional view of what the mitochondrial genome actually encodes.
MOTS-c belongs to a broader group known as mitochondrial-derived peptides (MDPs), which also includes humanin and small humanin-like peptides.
Research suggests these molecules can act as signals linking mitochondrial status with wider cellular responses.
Review mitochondrial-derived peptide research on PubMed
MOTS-c has attracted particular attention because its biology appears closely connected with metabolic stress and cellular adaptation.
Under certain experimental stress conditions, research indicates that MOTS-c can translocate to the nucleus and influence nuclear gene expression.
In other words, a peptide encoded within mitochondrial DNA may participate in communication from the mitochondria back to the nucleus.
Review MOTS-c mechanisms on PubMed
That is a very different picture of mitochondria from a passive cellular power source.
It suggests an active signaling system and explains why MOTS-c has become an important subject within mitochondrial peptide research.
3. Mitochondrial Peptide Research, MOTS-c and AMPK Signaling
One pathway repeatedly associated with MOTS-c research is AMP-activated protein kinase (AMPK).
AMPK functions as an important cellular energy sensor. Changes in cellular energy status can alter AMPK activity, helping coordinate processes involving energy production and consumption.
Published research and reviews describe MOTS-c activity involving the folate–AICAR–AMPK pathway, connecting the mitochondrial-derived peptide with cellular energy metabolism and stress adaptation.
View the MOTS-c review on PubMed
MOTS-c research has consequently expanded into experimental areas involving:
glucose metabolism
skeletal-muscle metabolism
metabolic stress
insulin-related signaling
exercise adaptation
inflammatory pathways
aging biology
Much of this work remains preclinical or mechanistic, and evidence from cell or animal models should not be presented as established human therapeutic effects.
But the research concept itself is compelling:
Mitochondria may produce peptide signals capable of influencing metabolic behavior elsewhere in the cell.
That possibility gives mitochondrial peptide research an entirely different dimension from conventional extracellular peptide signaling.
4. Can Mitochondria Be Deliberately Targeted?
MOTS-c begins inside mitochondrial genetics.
Another branch of mitochondrial peptide research asks almost the opposite question:
Can researchers design peptides from outside the mitochondrion that selectively interact with mitochondrial structures?
One of the most important examples is elamipretide, historically also known in research literature as SS-31.
Elamipretide is a mitochondria-targeting tetrapeptide whose research eventually focused heavily on its interaction with cardiolipin.
Cardiolipin is concentrated within the inner mitochondrial membrane and participates in the structural environment required for mitochondrial bioenergetics.
Research into elamipretide has associated its cardiolipin interaction with changes involving membrane properties, organization of cardiolipin-dependent proteins, mitochondrial structure and bioenergetic function.
Review elamipretide’s mitochondrial mechanism on PubMed
Then, in 2025, mitochondrial peptide research crossed an important regulatory threshold.
5. The First FDA-Approved Mitochondrial Cardiolipin Binder
On September 19, 2025, the U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide).
The indication is highly specific: improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.
The FDA describes Forzinity as a mitochondrial cardiolipin binder.
View the FDA Drug Trials Snapshot for Forzinity
Barth syndrome is a rare mitochondrial disease associated with abnormalities involving cardiolipin metabolism.
The FDA approval was based on an intermediate clinical endpoint involving knee-extensor muscle strength and was granted through the accelerated approval pathway. Continued approval may depend upon verification of clinical benefit in confirmatory research.
View the FDA prescribing information
That distinction matters.
This was not blanket FDA validation of “mitochondrial peptides,” nor does it establish that unrelated mitochondrial research compounds produce the same effects.
But from the perspective of mitochondrial peptide research, the milestone is significant.
A mitochondrial membrane component is no longer simply an interesting laboratory target.
A peptide designed around mitochondrial biology has reached regulatory approval as a cardiolipin-binding medicine for a defined mitochondrial disease.
6. Two Very Different Mitochondrial Peptide Strategies
MOTS-c and elamipretide illustrate two remarkably different approaches within mitochondrial peptide research.
MOTS-c: Mitochondria as the Source
MOTS-c is encoded within mitochondrial DNA.
Research investigates how this mitochondrial-derived peptide participates in metabolic and stress-response signaling, including communication between mitochondria and the nucleus.
Elamipretide: Mitochondria as the Target
Elamipretide is an engineered mitochondria-targeting peptide.
Instead of originating from mitochondrial DNA, it interacts with mitochondrial biology through its association with cardiolipin in the inner mitochondrial membrane.
Put simply:
MOTS-c → a signal originating from mitochondrial genetics
Elamipretide → an engineered peptide targeting mitochondrial membrane biology
The two compounds should not be treated as equivalents.
Their importance together is conceptual.
They demonstrate how mitochondria can exist on both sides of peptide biology—as a source of peptide signals and as a direct target of engineered peptides.
This source-versus-target distinction is one of the most important concepts emerging from mitochondrial peptide research.
7. Beyond Peptides: SLU-PP-332 and Mitochondrial Metabolic Research
Mitochondrial biology does not stop with peptides.
This is where another research area connects directly with the PepGen Lab catalog.
SLU-PP-332 — ERR Signaling and Mitochondrial Metabolism
Explore PepGen Lab SLU-PP-332 100 mg Capsules →
SLU-PP-332 is not a peptide.
It is a synthetic research compound investigated as an agonist of estrogen-related receptors (ERRs)—nuclear receptors associated with transcriptional programs involved in cellular energy metabolism and mitochondrial function.
Published preclinical research has reported ERR-dependent effects involving cellular respiration, oxidative metabolism and exercise-related metabolic responses.
This evidence is predominantly preclinical and should not be interpreted as established human clinical efficacy.
Its relevance is therefore different from both MOTS-c and elamipretide.
MOTS-c → mitochondrial-derived peptide signaling
Elamipretide → mitochondrial cardiolipin targeting
SLU-PP-332 → transcriptional regulation associated with mitochondrial metabolism
These are different molecular mechanisms, but all intersect with the expanding investigation of mitochondrial function.
This distinction is particularly important when placing non-peptide compounds alongside mitochondrial peptide research: sharing a mitochondrial research context does not make their molecular mechanisms equivalent.
View SLU-PP-332 at PepGen Lab →
MOTS-c and the PepGen Lab Research Landscape
MOTS-c itself has a natural scientific place within this research landscape whenever offered as part of the PepGen Lab research catalog.
Unlike SLU-PP-332, MOTS-c is directly part of mitochondrial-derived peptide biology.
Its research relevance centers on the unusual relationship between mitochondrial genetics, cellular stress sensing, metabolic signaling and nuclear communication.
For laboratories investigating mitochondrial peptide research, the distinction between these compounds is important:
MOTS-c → mitochondrial-derived peptide signaling
SLU-PP-332 → ERR-mediated metabolic and mitochondrial transcriptional research
Neither should be presented as equivalent to FDA-approved elamipretide, and neither inherits elamipretide’s regulatory status simply because all three intersect with mitochondrial research.
That separation keeps the science accurate while showing just how broad the mitochondrial research field has become.
Mitochondrial Peptide Research, Metabolism and the Biology of Aging
Mitochondrial function is also deeply connected with another major area of modern research:
aging biology.
Changes in mitochondrial function, metabolic flexibility, oxidative balance and cellular stress responses are repeatedly investigated within aging research.
Mitochondrial-derived peptides have therefore attracted attention as potential molecular links between mitochondrial status and organism-level aging biology.
Reviews of MOTS-c research describe associations with metabolic homeostasis, stress adaptation and aging-related experimental models. Some studies have also reported changes in circulating or tissue-associated mitochondrial-derived peptides with age.
Again, association and preclinical findings do not establish an anti-aging therapy.
But they raise an important research question:
Could mitochondrial signaling be one of the molecular interfaces connecting cellular energy status with biological processes associated with aging?
That question demonstrates why mitochondrial peptide research now intersects with fields extending well beyond classical bioenergetics.
The Mitochondrial Research Frontier Is Getting Bigger
For decades, peptide research largely focused on extracellular hormones, receptors and signaling molecules.
Mitochondrial biology is expanding that definition.
Scientists are now studying peptides that are:
encoded by mitochondrial DNA
produced as mitochondrial-derived signals
capable of communicating with the nucleus
engineered to target mitochondrial membranes
designed around mitochondrial lipid interactions
At the same time, non-peptide compounds are being investigated through nuclear receptors and transcriptional pathways associated with mitochondrial metabolism.
As a result, mitochondrial peptide research is moving from simply asking:
“How efficiently does the mitochondrion produce ATP?”
toward a much larger question:
“How can mitochondrial signaling, structure and metabolic regulation be investigated—and deliberately targeted—at the molecular level?”
From Research Curiosity to Regulatory Milestone
MOTS-c remains an emerging research subject.
SLU-PP-332 remains a preclinical research compound.
Elamipretide represents something different: a mitochondria-targeting peptide that progressed through clinical development and received FDA accelerated approval for a narrowly defined indication.
Those evidence levels must remain separate.
But viewed together, they illustrate how quickly mitochondrial peptide research and the wider mitochondrial-science field have evolved.
Mitochondria are no longer being investigated simply as cellular power plants.
They are becoming sources of molecular signals, regulators of metabolic adaptation, targets of engineered compounds and—in one specific FDA-approved case—a direct target of peptide-based medicine.
That transformation may make mitochondrial biology one of the most important frontiers in the next generation of peptide research.
Explore Related PepGen Lab Research
SLU-PP-332 — 100 mg Capsules, 60 Capsules →
The broader PepGen Lab research platform follows developments across mitochondrial signaling, metabolic pathways and emerging peptide science while maintaining a clear distinction between research compounds and approved medicines.
Scientific References & Verification
Wan W, et al. — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
Journal of Translational Medicine, 2023. Reviews MOTS-c mitochondrial encoding, nuclear translocation, AMPK-related signaling, metabolism and stress adaptation.
Zheng Y, et al. — MOTS-c: A Promising Mitochondrial-Derived Peptide for Therapeutic Exploitation
Reviews MOTS-c biology, metabolic signaling and the distinction between experimental findings and potential future applications.
Contemporary Insights Into Elamipretide’s Mitochondrial Mechanism of Action and Therapeutic Effects
Peer-reviewed 2025 review covering cardiolipin binding, mitochondrial membrane biology and bioenergetic mechanisms.
U.S. Food and Drug Administration — FDA Grants Accelerated Approval to First Treatment for Barth Syndrome
FDA announcement confirming the September 19, 2025 accelerated approval of Forzinity (elamipretide).
FDA Drug Trials Snapshot — Forzinity (elamipretide)
FDA description of Forzinity as a mitochondrial cardiolipin binder and summary of the clinical evidence supporting approval.
View FDA Drug Trials Snapshot →
Page Disclaimer
The information provided in this section is intended strictly for informational and research purposes only. Our articles discuss published studies, emerging scientific developments, and general laboratory topics related to research compounds. References to approved or investigational medicines are included solely to discuss developments in peptide science and drug-delivery research and do not imply that PepGen Lab products are equivalent to, approved as, or intended to be used as those medicines. PepGen Lab research compounds are intended strictly for laboratory research and in-vitro testing. Not for human or animal consumption.
Author: PepGen Lab Research Team